OHV

London, United Kingdom Founded: 2014 • Age: 12 yrs
Treatments against pathogens and diseases affecting animals are developed.
Annual revenue - Latest available
Total funding $150,000 1 rounds
Employees - Tracked headcount
Investors - Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About OHV

OHV is a company based in London (United Kingdom) founded in 2014. OHV has raised $150 thousand across 1 funding round. OHV operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.

  • Headquarter London, United Kingdom
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Legal Name One Health Ventures Limited
  • Date of Incorporation 06 Jun, 2014
  • Jurisdiction LONDON, UNITED KINGDOM
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $150 K (USD)

    in 1 rounds

  • Latest Funding Round
    $150 K (USD), Seed

    Feb 06, 2017

  • Investors
    Not available
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of OHV

OHV has successfully raised a total of $150K through 1 strategic funding round. The most recent funding activity was a Seed round of $150 thousand completed in February 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investments & Acquisitions by OHV

Investments
Premium access

Investment portfolio details for OHV

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - OHV

Premium access

Detailed financials for OHV

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Ohv Comparisons

OHV Primary company
Description
Treatments against pathogens and diseases affecting animals ...
Location
London, United Kingdom
Founded Year
2014
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for OHV

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of OHV

OHV operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
mRNA-based therapeutics for diseases including cancer and infections are developed.
Locked Locked Locked
Clinical diagnostics and drug discovery for immune diseases are provided.
Locked Locked Locked
Antiviral oral therapeutics are developed for infectious diseases and cancers.
Locked Locked Locked
Developer of immunotherapies for the treatment of infectious diseases and cancer
Locked Locked Locked
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
Locked Locked Locked
Developer of novel protein-based therapeutics using machine learning and biological engineering
Premium access

Detailed competitors of OHV

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Ohv

Premium access

Complete news archive for OHV

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about OHV

OHV was founded in 2014 and raised its 1st funding round 3 years after it was founded.

OHV is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.

OHV is a funded company, having raised a total of $150K across 1 funding round to date.

OHV was founded in 2014 in London, United Kingdom, within the biotechnology sector focused on one health initiatives. Treatments targeting pathogens and diseases that impact animals and potentially humans are developed. The initial project involves a vaccine against epsilon toxin, with additional efforts directed toward therapies for multiple sclerosis and vaccines against various toxins. Operations emphasize crossover applications between veterinary and human health.

OHV's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available